Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tezacaftor Clear all

Conditions: Cystic Fibrosis
Interventions: Elexacaftor-tezacaftor-ivacaftor exposure; Drug
Lead sponsor: Jennifer Taylor-Cousar; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cystic Fibrosis
Interventions: VX-659/TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 48
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cystic Fibrosis
Interventions: VX-581, Placebo, D-IVA, TEZ, ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cystic Fibrosis
Interventions: Triple combination therapy; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 12 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cystic Fibrosis (CF)
Interventions: Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring; Drug · Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida • St. Petersburg, Florida

Conditions: Cystic Fibrosis
Interventions: VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Birmingham, Alabama • Palo Alto, California • Stanford, California + 20 more

Conditions: Cystic Fibrosis
Interventions: Symdeko, Ivacaftor and Symdeko; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cystic Fibrosis
Interventions: VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 27
States / cities: Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA, TEZ/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Cystic Fibrosis
Interventions: Trikafta; Drug
Lead sponsor: Emory University; Other
Eligibility: 12 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Birmingham, Alabama • Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cystic Fibrosis
Interventions: RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more

Conditions: Cystic Fibrosis
Interventions: TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Cystic Fibrosis
Interventions: IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more

Conditions: Cystic Fibrosis
Interventions: Symdeko; Drug
Lead sponsor: George Solomon; Other
Eligibility: 6 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 11
States / cities: Denver, Colorado • New Haven, Connecticut • Orlando, Florida + 8 more

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 1 Year and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 18
States / cities: Orange, California • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Drug Drug Interaction
Interventions: Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg], Rifabutin 300mg; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: TEZ, IVA, VX-440, Matched Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 22
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Denver, Colorado

Search by objective public record fields.

Impact of Triple Combination CFTR Therapy on Sinus Disease.

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

Trikafta in Cystic Fibrosis Patients

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Personalized Theratyping Trial

A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY